Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2022-10-07 Transaction in Own Shar…
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title/header: "PureTech Health plc Transaction in Own Shares". It details the purchase of ordinary shares as part of a "Share Buyback Programme" on a specific date (6 October 2022), including the number of shares, highest/lowest/average price paid, and the resulting treasury share balance and total voting rights. This activity directly corresponds to the definition of 'Transaction in Own Shares'.
2022-10-07 English
Statement re Possible Offer
M&A Activity Classification · 100% confidence The document is an official announcement released via RNS (Regulatory News Service) on October 6, 2022. It explicitly references the 'CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE")' and discusses 'recent press speculation' regarding a 'possible combination' (takeover/merger talks) with Nektar Therapeutics. This content directly relates to M&A activity (Rule 2.4, Rule 2.7, Rule 2.6(a) of the Code). Although it discusses a potential takeover, which falls under M&A Activity (TAR), the document itself is a formal regulatory disclosure made via the RNS system, which is the primary mechanism for such announcements in the UK. Given the strong presence of RNS headers, the reference to the Takeover Code, and the nature of the announcement (a response to speculation about a potential offer), the most fitting primary classification is M&A Activity (TAR). However, since it is a formal regulatory announcement disseminated through the RNS system, and the content is specifically about a potential takeover bid, TAR is the most precise fit over the general RNS fallback.
2022-10-07 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states: 'PureTech Health PLC announces that it has purchased the following number of its ordinary shares... as part of its Share Buyback Programme.' It then details the number of shares purchased, the prices, and the resulting treasury share count. This directly corresponds to the definition of 'Transaction in Own Shares'. The filing type code for this activity is POS.
2022-10-06 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document text explicitly states: "PureTech Health plc Transaction in Own Shares" and details the purchase of ordinary shares as part of its "Share Buyback Programme." It provides specific transaction dates, volumes, and prices. This directly corresponds to the definition of a company reporting the purchase or sale of its own shares, which maps to the 'Transaction in Own Shares' category. This matches filing type code POS (Transaction in Own Shares). It is not an ER, IR, or 10-K as it focuses solely on share transactions, not comprehensive financial results. It is also not an RPA because it is the primary disclosure of the transaction, not just an announcement of a report's publication.
2022-10-05 English
6-K
Transaction in Own Shares Classification · 100% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, PureTech Health plc, reporting on a share repurchase program and detailing daily purchases of its own shares during September 2022. The content focuses on the company's transactions in its own shares, including quantities, prices, and dates, and references regulatory compliance for share repurchases. There is no financial statement or earnings data, no management discussion or analysis, no voting results, no merger or acquisition information, and no executive compensation details. The document is a regulatory filing reporting transactions in the company's own shares, which fits the category of Transaction in Own Shares (POS). The document length is sufficient and contains detailed transaction data, confirming it is not a mere announcement or certification but a substantive report of share repurchases.
2022-10-04 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states its purpose in the title section: 'Transaction in Own Shares'. It details the purchase of ordinary shares as part of a 'Share Buyback Programme' on a specific date (3 October 2022), including volume, highest, lowest, and VWAP prices. This directly corresponds to the definition of a Transaction in Own Shares (Share Repurchase/Issuance), which maps to the code POS.
2022-10-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.